Acta Haematologica最新文献

Artificial Intelligence and Venous Thromboembolism: a narrative review of applications, benefits, and limitations.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-04-08 DOI: 10.1159/000545760

Aya Mudrik, Orly Efros

{"title":"Artificial Intelligence and Venous Thromboembolism: a narrative review of applications, benefits, and limitations.","authors":"Aya Mudrik, Orly Efros","doi":"10.1159/000545760","DOIUrl":"https://doi.org/10.1159/000545760","url":null,"abstract":"Background: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a leading cause of cardiovascular morbidity and mortality. Artificial Intelligence (AI) holds promise for potential improvement of risk stratification, diagnosis, and management of VTE.Summary: This narrative review explores the applications, benefits, and limitations of AI in VTE management. AI models were shown to outperform conventional methods in identifying high-risk candidates for VTE prophylaxis treatments in several post-surgical settings. It has also been demonstrated to be efficient in the early detection of VTE events, particularly through point-of-care AI-guided sonography and computer tomography image processing. Data biases, model transparency, and the need for regulatory frameworks remain significant limitations in the full integration of AI into clinical practice.Key messages: AI has the potential to improve VTE care by enhancing risk stratification and diagnosis. The integration of AI-driven models into clinical workflows has the potential to reduce costs, streamline diagnostic processes, and ensure effective management of VTE. Safe and effective integration of AI into VTE care requires addressing its limitations., such as interpretability, privacy, and algorithmic bias.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-19"},"PeriodicalIF":1.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recombinant myeloid hematopoietic growth factors and clinical stimulation of acute myeloid leukemia cells: a narrative review.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-04-08 DOI: 10.1159/000545588

Jason S Gilbert, Daniel A Pollyea, Thomas J Walsh, Andreas H Groll, Hillard M Lazarus

{"title":"Recombinant myeloid hematopoietic growth factors and clinical stimulation of acute myeloid leukemia cells: a narrative review.","authors":"Jason S Gilbert, Daniel A Pollyea, Thomas J Walsh, Andreas H Groll, Hillard M Lazarus","doi":"10.1159/000545588","DOIUrl":"https://doi.org/10.1159/000545588","url":null,"abstract":"The advent of molecularly cloned hematopoietic growth factors (rhuG-CSF and rhuGM-CSF) enhanced the safety in treating acute myeloid leukemia (AML) by reducing the duration of neutropenia and thus decreasing the risks for infection. However, early in vitro studies demonstrated leukemia cell proliferation in response to these agents, raising reasonable concerns related to whether these factors can cause or contribute to relapse or progression of AML. Clinical studies using recombinant myeloid hematopoietic growth factors have supported their safety, as there is little or no clear evidence for an association with an increased risk of relapse in AML in patients, regardless of the hematopoietic growth factor used, or whether the setting of AML is newly diagnosed or relapsed/refractory. One exception may be in the pediatric population, though this effect might reflect a different isoform of the G-CSF receptor expressed on the AML cells, as this truncated receptor is also seen in severe congenital neutropenia (SCN) and aplastic anemia (AA), and underlies the increased myeloid malignancies that develop in these diseases after long-term exposure to growth factors. Otherwise, the current data support the use of rhuG-CSF and rhuGM-CSF in most patient populations with AML. Future studies should explore the factors influencing hematopoietic growth factor sensitivity in AML subpopulations to guide therapeutic decisions.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-15"},"PeriodicalIF":1.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of Pre-Treatment Sarcopenia in Patients newly diagnosed with Lymphoma.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-04-05 DOI: 10.1159/000545358

Charlotte Nørregaard Grønset, Mary Jarden, Jan Christensen, Martin Hutchings, Anders Tolver, Charlotte Suetta

引用次数: 0

Acquired FX Deficiency in Multiple Myeloma Without Concomitant Amyloidosis- A Rare Case Report.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-29 DOI: 10.1159/000545479

Roi Gat, Svetlana Trestman, Ilya Kirgner

引用次数: 0

Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-29 DOI: 10.1159/000545444

Ananya Chandrika Nanduri, Farah Ashraf, Swe Swe Hlaing, Michael Brister, Tapan M Kadia, Naveen Pemmaraju, Tulin Budak-Alpdogan

引用次数: 0

Mind-Body Intervention in Chronic Lymphocytic Leukemia During the Watch-and-Wait Phase: Benefits Linked to Intervention Duration.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-24 DOI: 10.1159/000545407

Shirley Shapira, Barak Mizrahi, Naama Hirschberger, Noa Rabinowicz, Adi Zoref-Lorenz, Natalie Flaks-Manov

{"title":"Mind-Body Intervention in Chronic Lymphocytic Leukemia During the Watch-and-Wait Phase: Benefits Linked to Intervention Duration.","authors":"Shirley Shapira, Barak Mizrahi, Naama Hirschberger, Noa Rabinowicz, Adi Zoref-Lorenz, Natalie Flaks-Manov","doi":"10.1159/000545407","DOIUrl":"https://doi.org/10.1159/000545407","url":null,"abstract":"Introduction: Mind-Body Interventions (MBI) are therapeutic practices that target the interactions between cognitive, emotional, and physiological systems to influence health outcomes. Previously, we demonstrated that MBI prolonged lymphocyte doubling time (LDT) and treatment-free survival (TFS) in treatment-naïve chronic lymphocytic leukemia (CLL) patients during the watch-and-wait phase. In this follow-up study, we investigated the long-term effects of MBI on TFS after the intervention ceased.Methods: 60 participants from the initial study (34 who received intervention vs. 26 controls) were followed for an additional period of 20 months. TFS was assessed from the end of the intervention to the initiation of CLL therapy or death, using Kaplan-Meier analysis and the log-rank test.Results: By the end of the follow-up, 9 participants who previously received MBI and 6 controls initiated CLL treatment. No significant difference in TFS was found between the groups (log-rank test p = 0.65).Conclusion: While MBI provided a clear advantage as long as it continued, our follow-up analysis suggests this effect diminishes after the intervention ends. Continuous or repeated MBI may be necessary for sustained improvements in TFS.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-6"},"PeriodicalIF":1.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Bibliometric Analysis of Immunotherapy in Diffuse large B-cell lymphoma from 2004 to 2024.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-21 DOI: 10.1159/000545152

Yanling Wu, Xiaomin Chen, Yang Liu, Yu Zhao, Lixiu Luo, Qiuwen Mi, Xiaoying Wen, Chunlan Huang

{"title":"A Bibliometric Analysis of Immunotherapy in Diffuse large B-cell lymphoma from 2004 to 2024.","authors":"Yanling Wu, Xiaomin Chen, Yang Liu, Yu Zhao, Lixiu Luo, Qiuwen Mi, Xiaoying Wen, Chunlan Huang","doi":"10.1159/000545152","DOIUrl":"https://doi.org/10.1159/000545152","url":null,"abstract":"Introduction: Immunotherapy in DLBCL (diffuse large B-cell lymphoma disease) has become an active research area with great value and potential. However, bibliometric research in this area is still sparse. Through bibliometric analysis, we aimed to visualize the research hot spots and trends of immunotherapy in DLBCL disease to help understand the future development of basic and clinical research.Methods: The Web of Science Core Collection database was searched for articles and reviews related to the immunotherapy of DLBCL from 2004 to 2024. VOSviewers, CiteSpace, and the R package \"bibliometrix\" were used to conduct the bibliometric analysis.Results: A total of 662 articles were included. The number of immunotherapy treatments in DLBCL increased year by year. The publications came from 55 countries, led by the United States and the People's Republic of China, and 1,349 institutions, with the leading research institutions being The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Leukemia & lymphoma is the journal with the most research, and Blood is the journal with the most co-citations. We identified 4833 authors, among which Young and Ken H had the most significant articles, while Neelapu SS had the largest number of co-citations. After analysis, the most common keyword is CAR T. CAR T cells (chimeric antigen receptor T cells immunotherapy), a current and developing area of research.Conclusions: This is the first bibliometric study to comprehensively summarize research trends and advances in immunotherapy in DLBCL disease. This information will provide a reference for researchers and healthcare providers in immunotherapy research by clarifying recent research frontiers and hotspots such as CAR T cells, bispecific antibodies, and so on.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-31"},"PeriodicalIF":1.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of T-Lymphocyte Subgroups at Diagnosis on The Prognosis of Chronic Lymphocytic Leukemia.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-17 DOI: 10.1159/000545269

Deniz Seyithanoglu, Esra Nazligul Sert, Murat Ozbalak, Metban Mastanzade, Simge Erdem, Mustafa N Yenerel

{"title":"The Effect of T-Lymphocyte Subgroups at Diagnosis on The Prognosis of Chronic Lymphocytic Leukemia.","authors":"Deniz Seyithanoglu, Esra Nazligul Sert, Murat Ozbalak, Metban Mastanzade, Simge Erdem, Mustafa N Yenerel","doi":"10.1159/000545269","DOIUrl":"10.1159/000545269","url":null,"abstract":"Introduction: Changes in the number and functional capacity of T-lymphocytes have been reported in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to examine the prognostic significance of T-lymphocyte subgroups in CLL patients.Methods: Eighty-three previously untreated patients were retrospectively enrolled and flow cytometry results at diagnosis were examined. No difference was found in T-lymphocyte parameters according to age, gender, and disease stage.Results: The CD4 and CD7 percentages, CD4/MBC (Malignant B Cell), CD8/MBC, and CD7/MBC values at diagnosis were significantly lower in patients with a progressive disease. T-lymphocyte percentages were significantly lower in deceased patients. In the univariate regression model, T-lymphocyte percentages, T-lymphocyte/MBC ratios, HLA-DR+ percentage, Rai stage (intermediate + high risk), Binet stage (B+C), and beta-2 microglobulin level had significant effects on both progression-free survival (PFS) and overall survival (OS); treatment status (yes) had a significant effect only on PFS, while age at diagnosis (≥ 65 years) had a significant effect only on OS. In the multivariate regression model, Rai stage, CD7/MBC ratio, and treatment status (yes) had a significant effect on PFS; Rai stage and CD8/MBC ratio had a significant effect on OS.Conclusion: Lower T-lymphocyte/MBC ratios at diagnosis could be a marker for higher risk of CLL progression.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematological evaluation and management of menorrhagia in adolescents: Lessons from adolescent heavy menstrual bleeding clinics. 青少年月经过多的血液学评估和管理：青少年大量月经出血诊所的经验教训。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-15 DOI: 10.1159/000545299

Marganit Benish, Adi Shitrit Yarhi, Ivan Budnik, Chagit Klieger, Noah Gruber, Yael Harel, Gili Kenet, Assaf Arie Barg, Sarina Levy-Mendelovich

{"title":"Hematological evaluation and management of menorrhagia in adolescents: Lessons from adolescent heavy menstrual bleeding clinics.","authors":"Marganit Benish, Adi Shitrit Yarhi, Ivan Budnik, Chagit Klieger, Noah Gruber, Yael Harel, Gili Kenet, Assaf Arie Barg, Sarina Levy-Mendelovich","doi":"10.1159/000545299","DOIUrl":"10.1159/000545299","url":null,"abstract":"Introduction: Heavy menstrual bleeding (HMB) poses a significant concern among adolescents and can arise from bleeding disorders. This study aimed to compare the clinical presentations and treatment of adolescents with HMB, distinguishing those with and without an underlying bleeding disorder.Methods: We conducted a retrospective analysis of adolescent patients presenting with HMB during 2014-2022 at specialized hematology-adolescent clinics in two tertiary referral hospitals in Israel. The study was approved by the Institutional Review Boards.Results: 77 adolescents underwent evaluation for HMB, and 19 of them were diagnosed with various bleeding disorders: platelet aggregation defects (5), immune thrombocytopenia (1), Glanzmann thrombasthenia (1), VWD type 1 (5), type 2A (1), type 3 (3), and coagulation factor deficiencies (3). Notably, 38 patients (49%) were hospitalized. A higher bleeding score (BAT) significantly correlated with hospitalization and a lower hemoglobin level (p<0.001). We did not find any significant differences between adolescents with or without a bleeding disorder regarding age of presentation, time from menarche, BAT, hemoglobin or platelet count.Conclusion: Our findings revealed the clinical presentations and treatments of adolescents with HMB are similar, regardless of the presence of a bleeding disorder. This emphasizes the importance of thorough evaluation in all adolescents presenting with HMB.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-15"},"PeriodicalIF":1.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Need for Concurrent Chemoimmunotherapy in Pediatric B-Cell Lymphoblastic Leukemia.

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-07 DOI: 10.1159/000545028

David McCall, Seth E Karol, Nicholas J Short

引用次数: 0